Evaluation of RECK mRNA and RECK protein in tissue and serum of breast cancer patients
Azza Hassan AbouGhalia, Eman Khairy, Manar Fouada, Hussein Abd Aleem Boshnak; Abou Ghalia, Azza;
Abstract
Background: Breast cancer (BC) is the most notorious females' cancer with high morbidity and mortality. RECK is
an inhibitor of matrix metalloproteinase, and cellular invasion. Although high expression levels of RECK has
been correlated with a better clinical outcome for several tumor types, its clinical significance for BC, remains
unclear. The present study aimed to investigate the expression of RECK gene in BC patients to evaluate its
clinical utility.
Methods: The current study included 120 breast tissue and serum specimens from patients with BC, and control
females. The two groups were matched for age, menopausal status, and the use of hormonal therapy or oral
contraceptive pills (OCP). The expression of RECK mRNA, and protein was determined by quantitative reverse
transcriptase polymerase chain reaction (qRT-PCR), and enzyme linked immunosorbent assay (ELISA), respectively.
Results: The expression of both RECK mRNA and protein was lower in tissues, and sera samples obtained from
BC patients than the control group. The tissue levels of RECK mRNA and RECK protein were high in premenopausal and OCP users. The sensitivity of RECK mRNA in tissue and serum was 100%. Both mRNA and
protein levels of RECK in serum were positively correlated with their levels in breast tissue.
Conclusion: These findings illustrate the clinical value of RECK as a molecular marker for BC, and the feasibility
of liquid biopsies to determine RECK expression.
an inhibitor of matrix metalloproteinase, and cellular invasion. Although high expression levels of RECK has
been correlated with a better clinical outcome for several tumor types, its clinical significance for BC, remains
unclear. The present study aimed to investigate the expression of RECK gene in BC patients to evaluate its
clinical utility.
Methods: The current study included 120 breast tissue and serum specimens from patients with BC, and control
females. The two groups were matched for age, menopausal status, and the use of hormonal therapy or oral
contraceptive pills (OCP). The expression of RECK mRNA, and protein was determined by quantitative reverse
transcriptase polymerase chain reaction (qRT-PCR), and enzyme linked immunosorbent assay (ELISA), respectively.
Results: The expression of both RECK mRNA and protein was lower in tissues, and sera samples obtained from
BC patients than the control group. The tissue levels of RECK mRNA and RECK protein were high in premenopausal and OCP users. The sensitivity of RECK mRNA in tissue and serum was 100%. Both mRNA and
protein levels of RECK in serum were positively correlated with their levels in breast tissue.
Conclusion: These findings illustrate the clinical value of RECK as a molecular marker for BC, and the feasibility
of liquid biopsies to determine RECK expression.
Other data
| Title | Evaluation of RECK mRNA and RECK protein in tissue and serum of breast cancer patients | Authors | Azza Hassan AbouGhalia, Eman Khairy, Manar Fouada, Hussein Abd Aleem Boshnak ; Abou Ghalia, Azza | Keywords | Breast cancer, RECK, qRT-PCR, ELISA, Circulating Biomarker | Issue Date | 2018 | Journal | Gene Reports |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.